1. Work productivity loss is determined by fatigue and reduced quality of life in employed inflammatory bowel disease patients
- Author
-
Cyriel Y. Ponsioen, Svend T. Rietdijk, Marjolijn Duijvestein, Mark Löwenberg, Krisztina Gecse, Angela G. E. M. de Boer, Sara van Gennep, Geert R. D'Haens, Nanne K. H. de Boer, Marieke E Gielen, Graduate School, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Gastroenterology and Hepatology, Public and occupational health, APH - Societal Participation & Health, APH - Quality of Care, Gastroenterology and hepatology, and Amsterdam Gastroenterology Endocrinology Metabolism
- Subjects
medicine.medical_specialty ,Disease ,Inflammatory bowel disease ,Vedolizumab ,Cohort Studies ,Indirect costs ,Quality of life ,Surveys and Questionnaires ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Fatigue ,Work productivity ,Hepatology ,business.industry ,Gastroenterology ,Inflammatory Bowel Diseases ,medicine.disease ,Ulcerative colitis ,Chronic Disease ,Quality of Life ,Colitis, Ulcerative ,business ,medicine.drug ,Cohort study - Abstract
OBJECTIVE: Inflammatory bowel disease (IBD) patients experience problems at work resulting in work productivity loss driving indirect healthcare costs. We aimed to find determinants for work productivity loss in employed IBD patients while correcting for disease severity according to prior and active maintenance treatment. METHODS: In this longitudinal multicentre cohort study, 510 employed IBD patients completed online questionnaires during 18 months follow-up. Work productivity, fatigue and health-related quality of life (HRQL) were measured using the Work Productivity and Activity Impairment questionnaire, the Multidimensional Fatigue Inventory (score 20-100) and Short-Inflammatory Bowel Disease Questionnaire (score 10-70). Linear mixed model analyses including random, repeated and fixed effects were performed. RESULTS: Fatigue (β 0.22; 95% CI, 0.12-0.32) and reduced HRQL (β -1.15; 95% CI, -1.35 to -0.95) were the strongest determinants for work productivity loss in employed IBD patients. Clinical disease activity (β 9.50, 95% CI 6.48-12.51) and corticosteroid use (β 10.09, 95% CI 5.25-15.84) were associated with work productivity loss in the total IBD group and ulcerative colitis subgroup, but not in Crohn's disease patients. History of IBD-related surgery (β 9.41; 95% CI, 2.62-16.20) and vedolizumab use (β 12.74; 95% CI, 3.63-21.86) were significantly associated with work productivity loss in the ulcerative colitis subgroup. CONCLUSIONS: Fatigue and reduced HRQL were the strongest determinants for work productivity loss in employed IBD patients while correcting for disease severity and activity. These results underline the importance of monitoring fatigue and HRQL in routine care to reduce work productivity loss and indirect costs.
- Published
- 2021